New drug tested to tame dangerous hormone flood
NCT ID NCT05307328
Summary
This study tested an investigational drug called SPI-62 to see if it could safely reduce the harmful excess cortisol caused by ACTH-dependent Cushing's syndrome. For 24 weeks, 26 adult participants received either the drug or a placebo, with an option to continue on the drug long-term. The goal was to control the disease by targeting a specific enzyme in the liver involved in cortisol production.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUSHING'S SYNDROME I are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carol Davila University of Medicine and Pharmacy
Bucharest, 050474, Romania
-
Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE)
Sofia, 1431, Bulgaria
-
Comprehensive and Interventional Pain Management Llp
Henderson, Nevada, 89052, United States
-
Mayo Clinic Cancer Center (MCCC) - Rochester
Rochester, Minnesota, 55905, United States
-
Medical University of Plovdiv
Plovdiv, 4002, Bulgaria
-
Medical University of Sofia
Sofia, 1431, Bulgaria
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Oregon Health & Science University (OHSU) - Northwest Pituitary Center
Portland, Oregon, 97239, United States
-
Southwest General Healthcare Center
Fort Myers, Florida, 33907, United States
-
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute (BNI) - Pituitary Center
Phoenix, Arizona, 85013, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Washington University School of Medicine - Center for Advanced Medicine (CAM)
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.